NanoViricides, Inc. Files Quarterly Report - Reports A Strong Cash Position Sufficient For Clinical Trials Of Its First Drug Candidate

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company"), has filed its quarterly report with the Securities and Exchange Commission on Thursday, November 15th, in a timely fashion. The submission can be downloaded from the SEC website at http://www.sec.gov/Archives/edgar/data/1379006/000114420413061915/v360486_10q.htm.

The Company reported that it had approximately $22.0M in current assets (cash, cash equivalents, collateral advance, and prepaid expenses) as of September 30, 2013, the end of the reporting quarter. The shareholder equity stood at approximately $11.75M. In comparison, the Company had approximately $15.5M in current assets plus collateral advances, and approximately $8M in shareholder equity as of June 30, 2013, the end of its financial year.

Help employers find you! Check out all the jobs and post your resume.